Subject: RE: Georgia PO - CIF Billing - 3rd
From: Tamar Gabunia </O=EXCHORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=E6CA04F38EC94D0CADAB9CBDF90FCDDE-TAMAR G>
To: Graeme Robertson <[email-masked]>
Cc: Ron Somers <[email-masked]>; Ekaterine Adamia </o=ExchOrganization/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89b4d31758d34f2cbdcfe688199f6941-Ekateri>; Aysan Murtezaoglu <[email-masked]>
Date: Mon, 13 Apr 2020 09:42:00 +0000

Dear Graeme

With this I am sharing the forecast for 2020 prepared by the treatment committee.

I would like to provide you with updated information on HCV Program implementation and adjusted plan on treatment.

From the beginning of the HCV program implementation, more then 66 000 HCV patients have already started treatment and more than 61 000 completed treatment.

At this stage, we have patients on treatment regimens, with MyHeppAll.

The monthly registration in the program in January and February was around 1800 patient. In March, due to the pandemic of the corona virus and isolation activities, patient inflow was about 400 patient. It should be noted that over the ten days of April, the number of registered beneficiaries is 400, so about 800 patients are expected in April. We think we will maintain the current (800 patient per month) enrolment on MyHeppAll in the lockdown months (April, May) and after that It is expected that the flow will increase to 1200 patient per month. With this picture of the inflow, the required amount of MyHeppAll  for current and new patients (which will be included in the program by the end of 2020+ 3 month buffer), besides arrived 24 003 bottles,  is about 35 000 bottles.

Should you have any questions please kindly let me know.

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

From: Graeme Robertson <[email-masked]>
Sent: Thursday, April 9, 2020 5:04 PM
To: Tamar Gabunia <[email-masked]>
Cc: Ron Somers <[email-masked]>; Ekaterine Adamia <[email-masked]>; Aysan Murtezaoglu <[email-masked]>
Subject: RE: Georgia PO - CIF Billing - 3rd

Thank you Tamar. I am glad the shipment arrived safely

Best wishes

Graeme

From: Tamar Gabunia <[email-masked]>
Sent: 09 April 2020 12:44
To: Graeme Robertson <[email-masked]>
Cc: Ron Somers <[email-masked]>; Ekaterine Adamia <[email-masked]>; Aysan Murtezaoglu <[email-masked]>
Subject: [EXTERNAL] RE: Georgia PO - CIF Billing - 3rd

Dear Graeme

Many thanks for your follow up. I apologize for delayed response on your enquiries regarding the forecast. I am waiting the treatment committee’s review and response on this. We’ll check tomorrow morning and get back to you immediately.

We did receive the latest shipment from Mylan. All went well.

With kind regards

პატივისცემით,

თამარ გაბუნია

მინისტრის პირველი მოადგილე

Sincerely,

Tamar Gabunia, MD, MPH

First Deputy Minister

From: Graeme Robertson [mailto:[email-masked]]
Sent: 9 April, 2020 15:11
To: Tamar Gabunia <[email-masked]>
Cc: Ron Somers <[email-masked]>; Ekaterine Adamia <[email-masked]>; Aysan Murtezaoglu <[email-masked]>
Subject: RE: Georgia PO - CIF Billing - 3rd

Dear Tamar,

I hope all well with you and you are staying safe and well during these difficult days.

I would like to follow up from our conversation last week. Please could you kindly send at your earliest convenience the forecast for sof/vel demand for the remainder of 2020 by month. I need this to instruct Mylan in time for the next set of shipments and my finance colleagues need to factor this into our budget.

Also did you receive the latest shipment from Mylan? Everything OK?

Thank you for your follow up.

Best wishes

Graeme

From: Tamar Gabunia <[email-masked]>
Sent: 02 April 2020 18:37
To: Dhruv Goel <[email-masked]>
Cc: Graeme Robertson <[email-masked]>; Ron Somers <[email-masked]>; Ekaterine Adamia <[email-masked]>; Anirudh Deshpande <[email-masked]>
Subject: [EXTERNAL] RE: Georgia PO - CIF Billing - 3rd

Many thanks!

From: Dhruv Goel [mailto:[email-masked]]
Sent: 2 April, 2020 21:03
To: Tamar Gabunia <[email-masked]>
Cc: Graeme Robertson <[email-masked]>; Ron Somers <[email-masked]>; Ekaterine Adamia <[email-masked]>; Anirudh Deshpande <[email-masked]>
Subject: FW: Georgia PO - CIF Billing - 3rd

Dear Minister Gabunia,

Nice to connect with you again. Hope you are safe and doing good.

Please find attached the shipping documents pertaining to the balance 14,667 bottles for SOF/VELPA which we plan to send by a flight which we are able to confirm as per details below:

FLIGHT DETAILS

TK 6237                 31.03.2020           BOM-ISL

TK 6374                 02.04.2020           ISL-TBS

Please let me know in case of any clarifications or concerns.

Thanks,
Dhruv

From: Dhruv Goel <[email-masked]>
Sent: 31 March, 2020 12:01 AM
To: 'Ron Somers ([email-masked])' <[email-masked]>
Cc: Anirudh Deshpande <[email-masked]>
Subject: Fwd: Georgia PO - CIF Billing - 3rd

Hi Ron,

Can you please have these documents reviewed along with the flight details mentioned below.

It would be great if you can provide go ahead by tomorrow for this. We will plan accordingly as this is a flight which we got after a lot of efforts.

Thanks

Dhruv

Get Outlook for iOS

From: Raja Sundaramurthy <[email-masked]>
Sent: Monday, March 30, 2020 10:45:09 PM
To: Dhruv Goel <[email-masked]>; Shahnawaz Khan <[email-masked]>; Bhaturaj Torane <[email-masked]>; Hemant Shekhawat <[email-masked]>; Hemant Patke <[email-masked]>; Sudhakar Siggireddi <[email-masked]>; Sai Rajeev Reddy Mareddy <[email-masked]>
Cc: Sandeep Ana <[email-masked]>; Prasanna P Pore <[email-masked]>; Anirudh Deshpande <[email-masked]>; Vipul Patel <[email-masked]>
Subject: RE: Georgia PO - CIF Billing - 3rd

FLIGHT DETAILS

TK 6237                 31.03.2020           BOM-ISL

TK 6374                 02.04.2020           ISL-TBS

Thanks & Regards

S. Raja

Tel :  30866666 /23550543  Extn :  6312

Cell :  800 800 1414
Fax No 30866699.

From: Dhruv Goel <[email-masked]>
Sent: Monday, March 23, 2020 3:09 PM
To: Shahnawaz Khan <[email-masked]>; Bhaturaj Torane <[email-masked]>; Hemant Shekhawat <[email-masked]>; Hemant Patke <[email-masked]>; Sudhakar Siggireddi <[email-masked]>; Sai Rajeev Reddy Mareddy <[email-masked]>
Cc: Sandeep Ana <[email-masked]>; Raja Sundaramurthy <[email-masked]>; Prasanna P Pore <[email-masked]>; Anirudh Deshpande <[email-masked]>; Vipul Patel <[email-masked]>
Subject: RE: Georgia PO - CIF Billing - 3rd

Thanks Shahnawaz,

We have asked for Clearance from Gilead. Kindly request you to please wait for the go-ahead before booking flights.

Thanks

Dhruv

From: Shahnawaz Khan <[email-masked]>
Sent: 23 March, 2020 2:51 PM
To: Bhaturaj Torane <[email-masked]>; Hemant Shekhawat <[email-masked]>; Hemant Patke <[email-masked]>; Sudhakar Siggireddi <[email-masked]>; Sai Rajeev Reddy Mareddy <[email-masked]>
Cc: Sandeep Ana <[email-masked]>; Raja Sundaramurthy <[email-masked]>; Prasanna P Pore <[email-masked]>; Anirudh Deshpande <[email-masked]>; Dhruv Goel <[email-masked]>; Vipul Patel <[email-masked]>
Subject: Georgia PO - CIF Billing - 3rd

Dear All,

Please add below shipment in your dispatch list.

Batches will be released by today evening

Bhaturaj/Hemant Please share PL

SO  & Allocation :-

Georgia - 801454580

SO No

Code

Description

Batch No

Qty

Mfg Date

Exp date

25386731

400537875

SOFO/VELP TAB 400/100MG 28BT MY EN/FR

3112906

TBC

28-Feb-20

31-Jan-22

3112907

TBC

02-Mar-20

28-Feb-20

Total

14667

Shipping instructions:-As per attached PO

1.       Seller

MLL

2.        Exporter

MLL

3.       Buyer

30003986 - Gilead Sciences Inc.

333 Lakeside Drive

Chris Milks

Foster City  94404

4.       Consignee

30008873 - LEPL “SOCIAL SERVICE AGENCY”

#144, TSERETELI AVE.

0159 TBILISI

GEORGIA

5.       Payment terms

60 days

Thanks & Regards

Shahnawaz Khan

Landline:080 66728572

This email message and any attachments are for the exclusive use of the intended addressee(s). This message may contain confidential, privileged and/or proprietary information, and unauthorized review, use or distribution by persons other than the intended addressee(s) is strictly prohibited and may be unlawful. Unintended transmission does not waive any privilege including attorney-client, attorney work product or claims to confidentiality. If you received this email in error or it was forwarded from recipients who received it in error, please contact me by return message and immediately destroy all electronic, paper and other versions of this message. Thank you.

Please think before you print.

View in other languages.

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England